Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Antimicrobial resistance of H. pylori to the outcome of 10-days vs 7-days moxifloxacin based therapy for eradication (CROSBI ID 549195)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Bago, Josip ; Belošić Halle, Željka ; Troskot Perić, Rosana ; Marušić, Marinko ; Bakula, Vinko ; Kučušec, Nastja ; Pevec, Branko ; Majstorović, Karolina Antimicrobial resistance of H. pylori to the outcome of 10-days vs 7-days moxifloxacin based therapy for eradication // Gut. 2008. str. A327-A327

Podaci o odgovornosti

Bago, Josip ; Belošić Halle, Željka ; Troskot Perić, Rosana ; Marušić, Marinko ; Bakula, Vinko ; Kučušec, Nastja ; Pevec, Branko ; Majstorović, Karolina

engleski

Antimicrobial resistance of H. pylori to the outcome of 10-days vs 7-days moxifloxacin based therapy for eradication

Antibiotic resistance decreses success of H. pylori eradication. Recently published results show a low rate of resistance and better compliance with moxifloxacin based regiments. Wherher 7 days moxifloxacine with lansoprasole and amoxycillin can be compared with 10 days moxifloxacine with lansoprasole and amoxycillin according to moxifloxacin resistance. Patients with non-ulcer dyspepsia and culture and histology positive H. pylori infection and (n=150)were randomly assigned into two groups. The first group (n=75) receive moxifloxacin 400 mg/d during 7 days and the other group (n=75) received moxifloxacin 400 mg/d during 10 days. All patients receive amoxycillin 1 g twice daily, lansoprasole 30 mg twice dailiy during 7 days. All H. pylori cultures were tested for sensitivity to moxifloxacin. 138 patients (92%) completed the study, 68 in the first group and 70 in the second. Eradicetion rates were, in the 7 days moxifloxacin group, 87%(57/68) and 90% in the second (63/70) according to the PP analysis ; p=n.s. Among 129 patients (86% of entire study group), 6% of strains were primary resistant to moxifloxacin. Eradication of moxifloxacin sensitive/resistant strains was 98%/66%, p<0.05 Antimicrobial resistance decreases the sucess of eradication. Concerning low moxifloxacine resistance, moxifloxacin based therapy for H. pylori eradication is promising to achieve the favourable eradication rate.

H. pylori; resistance; moxifloxacin

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

A327-A327.

2008.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Gut

0017-5749

Podaci o skupu

British Society of Gastroenterology Annual General Meeting

poster

10.03.2008-13.03.2008

Birmingham, Ujedinjeno Kraljevstvo

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost